Clinical Trial

Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This trial was designed to investigate the survival outcomes, response rates, and safety of patients with Barcelona-Clinical Hepatocellular Carcinoma (BCLC)-C-stage liver cancer by hepatic artery versus vein infusion of PD1/PDL1/CTLA4 inhibitor or their combinations.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-05-13; most recent amendment 2024-06-22.
Trial Details
NCT Number NCT03949231
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Conditions Liver Cancer
Enrollment 200 participants
Start Date 2019-01-01
Primary Completion 2029-01-01 (estimated)
Study Completion 2038-01-02 (estimated)
Updated on ClinicalTrials.gov 2024-06-26